Genome-wide mapping for clinically relevant predictors of lamotrigine- and phenytoin-induced hypersensitivity reactions.

Journal Article (Journal Article)

AIMS: An association between carbamazepine-induced hypersensitivity and HLA-A*3101 has been reported in populations of both European and Asian descent. We aimed to investigate HLA-A*3101 and other common variants across the genome as markers for cutaneous adverse drug reactions (cADRs) attributed to lamotrigine and phenytoin. MATERIALS & METHODS: We recruited patients with lamotrigine-induced cADRs (n = 46) and patients with phenytoin-cADRs (n = 44) and the 1958 British birth cohort was used as a control (n = 1296). HLA-A*3101 was imputed from genome-wide association study data. We applied genome-wide association to study lamotrigine- and phenytoin-induced cADR, and total cADR cases combined. RESULTS: Neither HLA-A*3101 nor any other genetic marker significantly predicted lamotrigine- or phenytoin-induced cADRs. CONCLUSION: HLA-A*3101 does not appear to be a predictor for lamotrigine- and phenytoin-induced cADRs in Europeans. Our genome-wide association study results do not support the existence of a clinically relevant common variant for the development of lamotrigine- or phenytoin-induced cADRs. As a predictive marker, HLA-A*3101 appears to be specific for carbamazepine-induced cADRs.

Full Text

Duke Authors

Cited Authors

  • McCormack, M; Urban, TJ; Shianna, KV; Walley, N; Pandolfo, M; Depondt, C; Chaila, E; O'Conner, GD; Kasperavičiūtė, D; Radtke, RA; Heinzen, EL; Sisodiya, SM; Delanty, N; Cavalleri, GL

Published Date

  • March 2012

Published In

Volume / Issue

  • 13 / 4

Start / End Page

  • 399 - 405

PubMed ID

  • 22379998

Pubmed Central ID

  • PMC3428903

Electronic International Standard Serial Number (EISSN)

  • 1744-8042

Digital Object Identifier (DOI)

  • 10.2217/pgs.11.165


  • eng

Conference Location

  • England